Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises is a research paper published in Trends in cancer (2021). On theSindex it has a DataRank of 0. It has been cited 37 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: 1P50CA217685-02
National Institutes of Health
Grant: T32 CA101642/CA/NCI NIH HHS/United States
National Medical Research Council
Grant: CSAINV16may008
University of Texas MD Anderson Cancer Center
Grant: CA016672
NCI NIH HHS
Grant: T32 CA101642
NCI NIH HHS
Grant: P30 CA016672
NCATS NIH HHS
Grant: UL1 TR003167
NCI NIH HHS
Grant: P50 CA217685
NCI NIH HHS
Grant: R01 CA181663
Bayer Fund
Novartis
Ipsen
AstraZeneca
Genentech
GlaxoSmithKline
Meso Scale Diagnostics
EMD Serono
Janssen Pharmaceuticals
FWCI
1.71
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals